Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 06, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 350,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,442.5457 pence per share.
- Treasury Shares Held: 199,091,678 shares (post-transaction).
- Shares in Issue: 5,787,344,724 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 350,000 shares on October 06, 2006, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 350,000 share repurchase based on the disclosed price of 1,442.5457 pence.
- Confirm the updated total share count (5,787,344,724 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the authorized buyback program.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial metrics.